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Abstract: Cost related to higher-level outcomes measurement is often very high. However, the 
cost burden is felt even more by smaller, less well-funded continuing medical education (CME) 
programs. It is possible to overcome financial and participant-related barriers to measuring Level 
6 outcomes, which are patient health outcomes. The Temple University School of Medicine’s 
Office for Continuing Medical Education developed a sequential tool for attaining cost-effective 
outcomes measurement for determining the likelihood of a CME intervention to produce signifi-
cant changes in physician performance. The appropriate selection of the CME topic and specific 
practice change indictors drive this tool. This tool walks providers through a simple YES or NO 
decision-making list that guides them toward an accurate prediction of potential programmatic 
outcomes. Factors considered during the decision-making process include whether: (a) the intended 
change(s) will have a substantial impact on current practice; (b) the intended practice change(s) 
are well supported by clinical data, specialty organization/government recommendations, expert 
opinion, etc; (c) the potential change(s) affects a large population; (d) external factors, such as 
system pressures, media pressures, financial   pressures, patient pressures, safety pressures, etc, 
are driving this intended change in performance; (e) there is a strong motivation on the part of 
physicians to implement the intended change(s); and (f) the intended change(s) is relatively 
easy to implement within any system of practice. If each of these questions can be responded 
to positively, there is a higher likelihood that the intended practice-related change(s) will occur. 
Such change can be measured using a simpler and less costly methodology.
Keywords: outcomes, outcomes measurement, cost-effective, evaluation tool, continuing 
medical education
Introduction
Outcomes measurement is a required part of continuing medical education (CME). 
The Accreditation Council for Continuing Medical Education (ACCME) requires that 
all providers analyze and evaluate the effectiveness of their CME activities. Providers 
must evaluate the effectiveness of their CME activities in meeting identified educational 
needs. Educational effectiveness can be evaluated at multiple levels. Moore’s seven-
level pyramid of outcomes measurement includes: participation, satisfaction, learning 
(declarative knowledge and procedural knowledge), competence, performance, patient 
health, and community health.1 CME providers are being called upon to demonstrate that 
their educational activities/programs result in better, more meaningful practice-based 
outcomes. Previously, measuring lower levels of outcomes – participation, satisfaction, 
or learning – was sufficient to meet ACCME expectations (Levels 1–3). ACCME now 
mandates that CME providers assess higher levels of outcomes; the impact of CME on 
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physician competence (Level 4), performance (Level 5), and 
patient health (Level 6) must be measured. Providers must 
analyze changes in learners’ competence, performance, and 
patient outcomes achieved as a result of the overall program’s 
activities/educational interventions.
Achieving higher levels of outcomes is not only expensive, 
but it is also time consuming. The most widely used and 
accepted methodologies to measure the outcomes of CME 
programs is audits and/or chart reviews of patients and com-
pleting patient report forms. These two protocols are time 
consuming, labor intensive, and expensive for both CME 
providers and participating physicians. Physicians have to 
spend 8–10 hours completing patient report forms, and CME 
providers have to provide some kind of monetary incentive 
for physicians. Most providers give financial incentive to par-
ticipating physicians to complete one patient report form. For 
25 patient report forms, the cost ranges from $1250–$2475 
per participating physician. This becomes financially burden-
some for CME providers.
In mid-2007, the Temple University School of Medicine 
CME Program was researching potential topics for a 
“performance improvement” educational activity in the 
area of cardiology. A scan of various cardiology news 
sources and discussions with Temple-affiliated   cardiologists 
established that the results of a major lipid trial (the Ezetimibe 
and   Simvastatin in Hypercholesterolemia Enhances 
Atherosclerosis Regression [ENHANCE] trial) were to 
be released during the upcoming American College of 
Cardiology (ACC) annual conference and these results were 
going to change the way physicians treated hyperlipidemia in 
patients using combination therapy. This seemed like a great 
opportunity for a performance improvement CME activity. 
A strategic plan was developed to design an Internet-based 
CME activity to be released soon after the ACC annual 
conference. A simple post survey methodology followed by 
telephone confirmation was selected to measure the change 
in the performance of physicians.
The CME program was designed to provide recommen-
dations to primary care physicians for taking care of their 
hyperlipidemic patients. The results from the ENHANCE 
study indicated that in patients with familial hypercholes-
terolemia, combination therapy with a statin (simvastatin) 
and ezetimibe did not result in a significant difference 
in changes in intima-media thickness, as compared with 
simvastatin alone, despite a decrease in the levels of low-
density lipoprotein cholesterol (LDL-C) cholesterol and 
C-reactive protein (CRP). Therefore, treatment plans for 
all patients on combination therapy need to be reassessed, 
with the emphasis on maximizing statin therapy and likely 
  discontinuation of ezetimibe.2 An Internet-based CME 
  program was designed, developed, and posted on Medscape 
2 weeks after the ACC meeting to help practicing physicians 
manage their patients appropriately. The recommendations 
made by the faculty are:
a.  LDL-C remains the primary treatment target
b.  Statin therapy remains the first-line treatment for 
hyperlipidemia
c.  Intensify statin therapy to achieve an LDL-C goal 
of ,70 mg/mL or LDL-C reduction of .50% in high-risk 
patients
•	 Titrate to maximize the tolerated dose of the statin
•	 Switch to a more potent statin
d.  If treatment with a statin alone is not sufficient to achieve 
the treatment goal or the use of high-dose statin therapy 
is not appropriate, initiate combination therapy; begin 
by adding a fibrate or niacin before the combination of a 
statin and ezetimibe
e.  Use CRP as a surrogate marker to refine risk assessment 
of asymptomatic patients at low-to-intermediate cardio-
vascular disease risk who would benefit from a more 
aggressive risk-reduction strategy.
Material and methods
Study design
Over 8000 healthcare professionals participated in the 
activity and 1047 CME certificates were issued. Certain 
physician information, such as ethnicity, years in practice, 
and number of patients seen in a week, was not known. Of the 
1047 physicians who received CME certificates, 200   primary 
care physicians were randomly selected for a post   survey 
consisting of six questions. The survey was mailed to 
participants 120 days post activity. The participants who 
responded to the survey were called 60 days after receiving 
the survey results to reconfirm the responses.
The survey questions
Physicians were asked if they changed their behavior for each 
of six behaviors related to the CME initiative (Appendix 1).
Statistical methods
The responses were on a five-point scale where five equals 
“strongly agree” and one equals “strongly disagree”. The 
intended outcome was for the respondents to change their 
behavior; a “strongly agree” (coded as a 5) response indicates 
success for the program. Descriptive statistics (means and 
frequency summaries) were used to analyze the data. With 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
366
Somasekhar et alInternational Journal of General Medicine 2012:5
reference to the means and item frequencies, a mean of ∼4 
(for item 1) on a five-point scale indicates success.
Pearson product moment correlations were calculated to 
measure the degree of relationship among the six behavioral 
outcomes represented by the item scores (see Table 2). For 
example, there is a relatively strong relationship between 
how the respondents answered item 1 and how they answered 
item 3.
Results
The results of these studies are shown in Table 1. Forty-eight 
participants responded to the questions. For questions 1–4, 
the mean and item frequency ranged from 3.98–4.30. Forty-
four participants out of 48 were using surrogate markers to 
identify patients at high risk for cardiovascular events who 
may benefit from intensive therapy. Question 2 was added 
to the analysis because, according to the Framingham Heart 
Study, cigarette smoking increases the risk of heart disease, 
an issue that was discussed by faculty.3 Thirty-nine out of 
48 were using some kind of intervention for smoking cessa-
tion. It was interesting to note that 44 physicians out of 48 
think it is essential to achieve a reasonable goal of ,70 mg/
dL LDL for patients with coronary heart disease (CHD) 
and diabetes. On the other hand, only 40 physicians out of 
48 reported they would prescribe combination therapies to 
achieve LDL-C reductions of .50%. Thirty-eight physi-
cians out of 48 had changed their performance as far as the 
use of a statin with ezetimibe as a preferred lipid-lowering 
combination therapy.
A significant correlation between questions on the 
post survey was observed using Pearson product moment 
  correlations to measure the degree of relationship among 
the six behavioral outcomes represented by the item 
scores. There were three significant positive correlations 
between Questions 3 and 1, Questions 6 and 3, and 
  Questions 6 and 4. As physicians reported that they used 
more “surrogate markers to identify patients at high risk 
of cardiovascular events who may benefit from intensive 
therapy,” they also reported that they “more frequently 
helped achieve a reasonable goal of ,70 mg/dL LDL for 
patients with CHD and diabetes” (P , 0.01). The physi-
cians who reported they “prescribed combination therapies 
to achieve LDL-C reductions of .50%,” also reported 
that they “more frequently prescribed use of a statin with 
niacin as a preferred lipid-lowering combination therapy” 
(P , 0.01). Similarly, physicians who reported they “more 
frequently helped achieve a reasonable goal of ,70 mg/dL 
LDL for patients with CHD and diabetes,” also reported 
that they “more frequently prescribed use of a statin with 
niacin as a preferred lipid-lowering combination therapy” 
(P , 0.01) (see Table 2).
A paired t-test was conducted to determine whether there 
were significant differences in mean responses between 
  questions on the post survey.
Table 3 below shows that on average, respondents indi-
cated achieving a reasonable goal of ,70 mg/dL LDL for 
patients with CHD and diabetes was more important than 
using surrogate markers to identify patients at high risk 
of cardiovascular events who may benefit from intensive 
therapy. On the other hand, it was more important to use 
surrogate markers to identify patients at high risk of cardio-
vascular events who may benefit from intensive therapy than 
to use a statin with ezetimibe as a preferred lipid-lowering 
combination therapy or use a statin with niacin as a preferred 
lipid-lowering combination therapy. Similarly, it was more 
important to insist that a patient with hypercholesterolemia 
who smokes enroll in a smoking cessation program than 
to use a statin with ezetimibe as a preferred lipid-lowering 
combination therapy or use a statin with Niacin as a preferred 
lipid-lowering combination therapy. Most interestingly, the 
use of a statin with ezetimibe as a preferred lipid-lowering 
combination therapy was lowest on the responders’ list.
Table 1 Average agreement rating* with concept and percentage of respondents who indicate “I have changed” or “I have not 
changed” my practice behavior in this area
Questions Mean Changed % Not changed %
1.    Use surrogate markers to identify patients at high risk of cardiovascular events  
who may benefit from intensive therapy
3.98 91.7 8.3
2.    Insist that a patient with hypercholesterolemia who smokes enroll in a smoking  
cessation program
4.18 81.3 18.7
3.  help achieve a reasonable goal of ,70 mg/dL LDL for patients with ChD and diabetes 4.30 91.7 8.3
4.  Prescribe combination therapies to achieve LDL-C reductions of .50% 4.00 83.3 16.7
5.  Use a statin with ezetimibe as a preferred lipid-lowering combination therapy 3.21 79.2 20.8
6.  Use a statin with niacin as a preferred lipid-lowering combination therapy 3.75 81.3 18.7
Note: *The Likert scale values ranged from 1–5 where 1 indicates low agreement and 5 indicates high agreement.
Abbreviations: ChD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol.
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Discussion
Achieving higher levels of outcomes 
measurement is not an easy task
Measuring higher levels of outcomes is complicated and 
usually requires a larger study population. In addition, it 
requires extended follow-up and more elaborate outcome 
methodologies, such as audits, chart reviews, electronic 
health records, health plan data, registries, and patient sur-
veys. Patient level outcomes (changes in patient health status) 
require access to physicians’ actual patient data and may be 
limited by Health Insurance Portability and Accountability 
Act regulations. There are a number of studies showing that 
all formats of CME are effective in changing physicians’ 
behavior to some extent.4–20 However, in our experience, 
these changes are small and sometimes difficult to measure 
even using chart reviews.
In this study, we have demonstrated that even a single 
intervention can have a drastic effect on the behavior 
of   physicians. As the face of CME is changing, there is 
tremendous pressure on educators to design CME activities 
around the problems in the health system and measure their 
effectiveness at the population or system level. The impor-
tant thing to remember is that large numbers of physicians 
practice in communities; these physicians need good 
evidenced-based education, and as educators, we have to 
create education in all different formats to fulfill the needs 
of our community physicians. Based on our experience, we 
developed a sequential tool to determine the likelihood of 
a CME activity resulting in significant changes that can be 
measured using a simple and cost-effective methodology.
Description of a sequential tool 
for driving cost-effective outcomes 
measurement
It is possible to overcome financial and participant-related 
barriers to measuring Level 6 outcomes. Based on the results 
of this study, we developed a tool for projecting and evaluat-
ing variables related to cost-effective outcomes measurement. 
This tool describes the likelihood of a CME intervention to 
produce significant changes in physician performance using 
simple and cost-effective measurement tools. Appropriate 
selection of the CME topic and specific practice change 
indictors drive this tool (see Table 4). This evaluative tool 
starts with careful consideration of the topic and intended/
needed/recommended changes in practice. If the answer 
to each of these questions is “yes”, then there is a higher 
likelihood that the intended practice-related change(s) will 
occur and such change can be measured using simpler and 
less costly methodology.
Will the intended change(s) have  
a substantial impact on current practice?
The selection of a CME topic is the most crucial step 
to study the changes in physician performance. When 
the change is small, one has to use both qualitative 
Table 3 Preferences between six items on the post survey
Question 
pairs
Respondents Mean 
difference
Std deviation 
difference
95% confidence interval   
of the difference
P values
Lower Upper
Q1, Q3 43 -0.33 0.61 -0.51 -0.14 P , 0.001
Q1, Q5 39 0.87 1.22 0.48 1.27 P , 0.001
Q1, Q6 39 0.28 0.79 0.02 0.54 P , 0.05
Q2, Q5 37 1.14 1.13 0.76 1.51 P , 0.001
Q2, Q6 37 0.51 0.93 0.20 0.82 P , 0.01
Q3, Q4 40 0.35 0.89 0.06 0.64 P , 0.05
Q3, Q5 38 1.13 1.12 0.76 1.50 P , 0.001
Q3, Q6 40 0.60 0.74 0.36 0.84 P , 0.001
Q4, Q5 38 0.79 1.12 0.42 1.16 P , 0.001
Q4, Q6 40 0.25 0.78 0.00 0.50 P , 0.05
Q5, Q6 37 -0.57 1.32 -1.01 -0.13 P , 0.05
Table 2 Correlations among the six items on the post survey
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6
Item 1 1.00 0.27 0.52** 0.06 -0.03 0.22
Item 2 0.27 1.00 0.27 0.15 0.29 0.18
Item 3 0.52** 0.27 1.00 0.17 0.20 0.34*
Item 4 0.06 0.15 0.17 1.00 0.28 0.41**
Item 5 -0.03 0.29 0.20 0.28 1.00 -0.09
Item 6 0.22  0.18 0.34* 0.41** -0.09 1.00
Notes: *P , 0.05; **P , 0.01.
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and quantitative methodologies to measure a clinically 
significant change. On the other hand, when there is a 
major shift in the paradigm due to negative clinical results, 
the change is significant and can be easily measured using 
low-cost measurement tools.
Is the intended practice change(s) 
well supported by clinical data, 
specialty organization/government 
recommendations, expert opinion, etc?
There should be a high level of consensus/agreement among 
health care providers/experts/regulatory agencies regarding the 
effectiveness and safety of therapeutic agents. In this particular 
case, it was crucial to use lipid-lowering strategies to reduce 
the risk of cardiovascular events. The use of lipid-lowering 
agents is considered the standard of care for a large segment 
of the US population to reduce both the risk of developing 
cardiovascular disease and the risk of a future event (primary 
and secondary prevention). These agents have well-understood 
mechanisms of action, well-documented efficacy, and minimal 
side effects. The use of a statin is supported by large clinical 
trials, and practice guidelines have been developed by associa-
tions and opinion leaders (ie, the American Heart Association, 
American College of Cardiology, National Cholesterol Educa-
tion Program Adult Treatment Panel III). There is compelling 
data from large, well-designed, randomized, double-blinded, 
multicenter clinical trials reinforcing current treatment recom-
mendations and best practices.
Does this potential change affect  
a large population?
The patient population potentially affected by the intended 
  performance change should be large. Over 102   million   American 
adults suffer from dyslipidemia (total cholesterol . 200 mg/dL).21 
Over a third of US adults have LDL-C . 130 mg/dL, which is 
associated with a higher risk of CHD.21 According to the   Centers 
for Disease Control and Prevention, only half of   Americans with 
high LDL-C receive treatment.22 Antihyperlipidemic agents are 
the second most frequently prescribed class of medication.23 
National Health Statistics Reports indicate that 200 million 
prescriptions for cholesterol drugs were written in 2007 and 
2008.23 As many as 30 million Americans (10% of the popula-
tion) are thought to be taking a statin to lower cholesterol. Sta-
tins are the most commonly used class of prescription drugs for 
US adults aged 60 years and over (nearly 45%).24 ENHANCE 
results directly affected ∼20 million patients who were taking 
ezetimibe in combination with a statin.25
Are there external outside factors driving 
this intended change(s) in performance?
Negative clinical study results are a primary motivating fac-
tor to change practice behavior due to press reports, media 
attention, fear of being sued, and new practice guidelines 
released by experts, national associations, and societies. 
The format and timelines of the educational intervention are 
very important. In this case, the online format of education 
was selected and the expert treatment guidelines, along with 
performance recommendations, were posted on the Internet 
2 weeks after the ACC meeting. The data that was shared 
was fresh and cutting edge.
Is there a strong motivation on the part 
of physicians to implement the intended 
change(s)?
Negative clinical outcomes studies frequently stimulate an 
urgency to implement practice changes. A large population 
was affected by the ENHANCE clinical data. Health care 
providers were eagerly waiting for clinical recommendations 
about how to manage these patient populations. In this 
study, a number of performance improvement indicators 
were defined, as shown in Table 1. These performance 
improvement indicators were also part of the recommendations 
made by the experts, as listed on the post activity survey. The 
experts and national associations recommended that lowering 
LDL-C is still the most important goal to reduce the risk of 
cardiovascular disease.
The behavior to encourage was that high-risk patients 
should be treated aggressively regardless of surrogate markers 
such as CRP. On the other hand, a CRP marker may be helpful 
to identify asymptomatic, low-to-intermediate risk patients 
who may benefit from more intensive therapy. Practicing 
physicians are looking for treatment guidelines to follow. 
Table  4  Tool  for  evaluating  the  potential  for  cost-effective 
outcomes measurement
1.    Will the intended change(s) have a substantial  
impact on current practice?
yes No
2.    Is the intended practice change(s) well supported  
by clinical data, specialty organization/government  
recommendations, expert opinion, etc
yes No
3.    Does this potential change affect a large  
population?
yes No
4.    Are there external factors driving this intended  
change in performance?
yes No
5.    Is there a strong motivation on the part 
 of physicians to implement the intended change
yes No
6.    Is the intended change(s) relatively easy to  
implement within any type of system of practice?
yes No
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Matching treatment programs to defined patient populations 
assists physicians in making the correct choices.
Is the intended change(s) relatively  
easy to implement within any type  
of system of practice?
This tool is based on criteria that physicians have no or 
limited perceived barriers. In this particular study, the physi-
cians had a number of other options, such as (1) maximizing 
the dose of statins; (2) using other combination therapies; 
and (3) sending patients to therapists for smoking cessa-
tion or life style changes. Minimizing barriers has a direct 
relationship with physicians’ abilities to implement changes 
in practice.
Conclusion
The tool developed and presented here sets constraints that 
allow providers to systematically evaluate the potential 
results gleaned from the outcomes measurement component 
of their initiative. They can thus minimize potential finan-
cial and human resource expenditures before dealing with 
the outcomes of a CME activity. This is particularly pivotal 
for smaller academic CME providers with severely limited 
financial resources that are eager to comply with outcomes 
measurement requirements that are critical to the ACCME 
accreditation process. Selecting topics and initiatives that 
provide the most opportunity for rich outcome data helps 
conserve these scarce resources.
It is our hope that adoption of this evaluative tool will 
assist CME providers in meeting the challenges of fiscal 
responsibility and accreditation regulation in this competitive 
era within the CME industry. The authors of this research 
encourage other CME providers to self-reflect on their plan-
ning process to improve this tool or to facilitate the develop-
ment of other tools to meet the growing needs of outcomes 
analysis of CME programs.
Annotation
There have been subsequent studies that have challenged 
the results of the ENHANCE clinical trial, Niacin, and CRP 
data. However, those studies have no impact on the outcomes 
of CME initiative.
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Appendix 1
Post activity survey
Please indicate on the scale, by circling a number or placing a check mark, to what degree your practice behaviors may have 
changed since attending the CME program entitled.
hot topics in hypercholesterolemia: impact of recent clinical trial data  
on clinical practice
1.  Use surrogate markers to identify patients at high risk of cardiovascular events who may benefit from intensive 
therapy
    Use more frequently _____________________________________Use less often
  [5]  [4]  [3]  [2]  [1]
 I have not changed my practice behavior in this area
2.  Insist that a patient with hypercholesterolemia who smokes enroll in a smoking cessation program
    Insist more frequently ______________________________________Insist less often
  [5]  [4]  [3]  [2]  [1]
 I have not changed my practice behavior in this area
3.  Help achieve a reasonable goal of ,70 mg/dL LDL for patients with CHD and diabetes
    Help achieve more frequently _____________________________Help achieve less often
  [5]  [4]  [3]  [2]  [1]
 I have not changed my practice behavior in this area
4.  Prescribe combination therapies to achieve LDL-C reductions of .50%
    Use more frequently _______________________________________Use less often
  [5]  [4]  [3]  [2]  [1]
 I have not changed my practice behavior in this area
5.  Use a statin with ezetimibe as a preferred lipid-lowering combination therapy
    Prescribe more frequently _________________________________Prescribe less often
  [5]  [4]  [3]  [2]  [1]
 I have not changed my practice behavior in this area
6.  Use a statin with niacin as a preferred lipid-lowering combination therapy
    Prescribe more frequently ________   __________________________Prescribe less often
  [5]  [4]  [3]  [2]  [1]
 I have not changed my practice behavior in this area
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